A new study conducted at Cedars-Sinai reveals how the cholesterol-reducing drug evolocumab prevents heart attacks in people ...

[Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab (Repatha, Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015.

A double-blind, randomized, placebo-controlled, multicenter study to evaluate the impact of evolocumab on major cardiovascular events in patients at high cardiovascular risk without prior myocardial ...